Monitor for future disclosures on financial terms, manufacturing volume commitments, or regulatory progress of licensed products; the partnership may improve Celularity’s capital efficiency but lacks near-term financial visibility.
Price Chart
Executive Summary
Celularity Inc. announced a strategic commercialization partnership with NEXGEL, Inc., licensing its established biomaterial products and pipeline programs for wound care and orthopedics. Celularity will serve as the exclusive manufacturer, leveraging its FDA-compliant facility in New Jersey, while NEXGEL takes responsibility for commercialization. The deal is expected to close by April 15, 2026, subject to customary conditions.
Key Facts
- Celularity licensed commercial products (Biovance, Natalin, Acelagraft, etc.) and pipeline programs (SPARK, FUSE, ORCHID) to NEXGEL.
- Celularity will be the exclusive manufacturer at its Florham Park, NJ facility.
- The transaction is expected to close by April 15, 2026, subject to customary closing conditions.
- No financial terms (e.g., upfront payment, milestone amounts, royalty rates) were disclosed in the press release.
- Management highlights strategic focus on contract manufacturing and capital efficiency.
Financial Impact
Potential future revenue from manufacturing, milestones, and royalties — magnitude unknown due to lack of disclosed financials
Risk Factors
- Transaction may not close on time or at all due to unmet conditions.
- No guarantee of meaningful manufacturing revenue if NEXGEL fails to commercialize products successfully.
- Lack of disclosed financial terms limits ability to assess true economic value to Celularity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3254647 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 10-K/A | $1.26 | awaiting T+60 | — | $0.8024 (+36.32%) |
Sep 30, 2026 27d ago | Press Release | $1.35 | awaiting T+60 | — | $0.8024 (−40.56%) |
Sep 29, 2026 27d ago | 8-K | $1.35 | awaiting T+60 | — | $0.8024 (−40.56%) |
Sep 28, 2026 29d ago | SC 13D/A | $1.40 | awaiting T+60 | — | $0.8024 (+42.69%) |
Sep 28, 2026 29d ago | 8-K | $1.40 | awaiting T+60 | — | $0.8024 (+42.69%) |
Sep 24, 2026 4w ago | Press Release | $1.32 | awaiting T+60 | — | $0.8024 (−39.21%) |
Sep 14, 2026 6w ago | 8-K | $1.40 | awaiting T+60 | — | $0.8024 (−42.69%) |
Aug 25, 2026 8w ago | Press Release | $0.8804 | awaiting T+60 | — | $0.8024 (+8.86%) |
Aug 7, 2026 11w ago | 8-K | $0.6866 | awaiting T+60 | — | $0.8024 (−16.87%) |
Jun 30, 2026 17w ago | 8-K | $0.5979 $1.15 | ▼ −92.34% | ▼ −88.78% | $0.8024 (−34.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers